WO2018198925A1 - 貼付剤 - Google Patents
貼付剤 Download PDFInfo
- Publication number
- WO2018198925A1 WO2018198925A1 PCT/JP2018/016117 JP2018016117W WO2018198925A1 WO 2018198925 A1 WO2018198925 A1 WO 2018198925A1 JP 2018016117 W JP2018016117 W JP 2018016117W WO 2018198925 A1 WO2018198925 A1 WO 2018198925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- adhesive layer
- butorphanol
- pressure
- sensitive adhesive
- mass
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Definitions
- the present invention relates to a patch, and more particularly to a patch containing butorphanol and / or a pharmaceutically acceptable salt thereof.
- Butorphanol is a generic name for 17- (cyclobutylmethyl) morphinan-3,14-diol (17- (Cyclobutymethyl) morphinan-3,14-diol) having a morphinan skeleton molecular structure.
- Butorphanol is a drug classified as an opioid analgesic, and is generally used as an injection containing butorphanol tartrate, which is a tartrate addition salt thereof.
- Butorphanol is also disclosed as, for example, N-cyclobutylmethyl-3,14-dihydroxymorphinan in US Pat. No. 3,775,414 (Patent Document 1).
- Non-Patent Document 1 describes the use of butorphanol as a drug for a transdermal absorption preparation.
- International Publication No. 2016/060122 includes a support layer and a pressure-sensitive adhesive layer, and the pressure-sensitive adhesive layer is selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof.
- a patch containing at least one kind, a higher aliphatic alcohol, and polyvinylpyrrolidone that is non-crosslinked and does not contain vinyl acetate as a constituent monomer is described.
- the adhesive base contained in the adhesive layer of such a patch a rubber-based adhesive base, an acrylic adhesive base, a silicone-based adhesive base, a urethane-based adhesive base, and the like are known. Yes.
- a support layer and an adhesive layer are provided, and the adhesive layer contains butorphanol and / or a pharmaceutically acceptable salt thereof and an adhesive base.
- the adhesive layer contains butorphanol and / or a pharmaceutically acceptable salt thereof and an adhesive base.
- butorphanol oxidant which is a decomposition product of butorphanol, is generated and contained in the pressure-sensitive adhesive layer.
- pharmaceuticals must satisfy various standards established for safety confirmation.
- the present invention has been made in view of the above demands, and an object of the present invention is to provide a patch in which the production of oxidized butorphanol is significantly suppressed as compared with conventional patches.
- the present inventors have a support layer and a pressure-sensitive adhesive layer, and the pressure-sensitive adhesive layer is selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof.
- a patch containing at least one kind hereinafter sometimes referred to as “butorphanol and / or a pharmaceutically acceptable salt thereof” and an adhesive base, in the adhesive layer, particularly sulfur as an antioxidant. It has been found that by further blending an antioxidant having atoms in the molecule, butorphanol oxidant is hardly produced, and the production can be remarkably suppressed even when stored for a long period of time.
- the patch of the present invention is a patch comprising a support layer and an adhesive layer, wherein the adhesive layer is at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof. And an adhesive base and an antioxidant having a sulfur atom in the molecule.
- the antioxidant having the sulfur atom in the molecule is preferably 2-mercaptobenzimidazole.
- the content of the antioxidant having the sulfur atom in the molecule is preferably 0.01 to 2.0% by mass with respect to the total mass of the pressure-sensitive adhesive layer. .
- the adhesive base is at least one selected from the group consisting of a rubber-based adhesive base and a silicone-based adhesive base.
- the content of butorphanol and / or a pharmaceutically acceptable salt thereof in the pressure-sensitive adhesive layer is 3 with respect to the total mass of the pressure-sensitive adhesive layer in terms of butorphanol tartrate addition salt. It is preferably ⁇ 20% by mass.
- the pressure-sensitive adhesive layer further contains at least one selected from the group consisting of a tackifier and a plasticizer.
- the present invention it is possible to provide a patch in which the production of butorphanol oxidant is remarkably suppressed as compared with a conventional patch. Furthermore, according to the present invention, since the crystal precipitation in the pressure-sensitive adhesive layer is further sufficiently suppressed, it is possible to provide a patch particularly excellent in stability over time.
- the patch of the present invention is a patch comprising a support layer and an adhesive layer, wherein the adhesive layer is at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof; It contains an adhesive base and an antioxidant having a sulfur atom in the molecule.
- the patch of the present invention comprises a support layer and an adhesive layer.
- the patch of the present invention preferably includes the support layer and the pressure-sensitive adhesive layer laminated on at least one surface of the support layer.
- the support layer is not particularly limited as long as it can support the pressure-sensitive adhesive layer, and any known support layer for a patch can be appropriately employed.
- Examples of the material of the support layer according to the present invention include polyolefins such as polyethylene and polypropylene; ethylene-vinyl acetate copolymers, vinyl acetate-vinyl chloride copolymers, polyvinyl chloride, etc .; polyamides such as nylon; polyethylene terephthalate (PET), polyesters such as polybutylene terephthalate and polyethylene naphthalate; cellulose derivatives; synthetic resins such as polyurethane; and metals such as aluminum.
- PET polyethylene terephthalate
- polyesters such as polybutylene terephthalate and polyethylene naphthalate
- synthetic resins such as polyurethane
- metals such as aluminum.
- polyester and polyethylene terephthalate are preferable from the viewpoint of drug non-adsorption and drug non-permeability.
- the form of the support layer examples include films; sheets such as sheets, sheet-like porous bodies, and sheet-like foams; fabrics such as woven fabrics, knitted fabrics, and nonwoven fabrics; foils; and laminates thereof. It is done.
- the thickness of the support layer is not particularly limited, but is preferably within the range of 5 to 1000 ⁇ m from the viewpoint of workability and ease of manufacture when applying the patch.
- the patch of the present invention may further include a release liner on the surface of the pressure-sensitive adhesive layer opposite to the support layer.
- release liners include polyolefins such as polyethylene and polypropylene; ethylene-vinyl acetate copolymers, vinyl acetate-vinyl chloride copolymers, polyvinyl chloride and the like; polyamides such as nylon; polyesters such as polyethylene terephthalate; cellulose derivatives; Examples thereof include synthetic resins such as polyurethane, films and sheets made of materials such as aluminum and paper, and laminates thereof.
- release liners have been subjected to a release treatment such as a silicone-containing compound coat or a fluorine-containing compound coat on the surface in contact with the pressure-sensitive adhesive layer so as to be easily peeled from the pressure-sensitive adhesive layer.
- a release treatment such as a silicone-containing compound coat or a fluorine-containing compound coat on the surface in contact with the pressure-sensitive adhesive layer so as to be easily peeled from the pressure-sensitive adhesive layer.
- a release treatment such as a silicone-containing compound coat or a fluorine-containing compound coat
- the pressure-sensitive adhesive layer according to the present invention contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof as a drug.
- butorphanol means 17- (cyclobutylmethyl) morphinan-3,14-diol (17- (Cyclobutylmethyl) morphin-3,14-diol) represented by the molecular formula C 21 H 29 NO 2. Point to.
- the form of butorphanol contained in the pressure-sensitive adhesive layer may be a free form (free form) or a pharmaceutically acceptable salt thereof, and is produced during and / or produced.
- the pharmaceutically acceptable salt of butorphanol in the preparation may be desalted into a free form, and may be one of these or a mixture of two or more.
- the pharmaceutically acceptable salt of butorphanol is preferably an acid addition salt from the viewpoint that the stability of the drug tends to be further improved.
- the acid of the acid addition salt examples include hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, phosphorous acid, hydrobromic acid, maleic acid, malic acid, ascorbic acid, tartaric acid, lauric acid, stearic acid, palmitic acid, and olein.
- examples include acids, myristic acid, lauryl sulfate, linolenic acid, and fumaric acid.
- the pharmaceutically acceptable salt of butorphanol is preferably a tartaric acid addition salt (butorphanol tartrate) represented by the following structural formula (1).
- the content of butorphanol and / or a pharmaceutically acceptable salt thereof contained in the pressure-sensitive adhesive layer is preferably 3 to 20% by mass based on the total mass of the pressure-sensitive adhesive layer in terms of butorphanol tartaric acid addition salt, The content is more preferably 3 to 15% by mass, and further preferably 3 to 12% by mass. If the content of butorphanol and / or a pharmaceutically acceptable salt thereof is less than the lower limit, the skin permeability of butorphanol tends to decrease. On the other hand, if the content exceeds the upper limit, butorphanol crystals tend to precipitate. Or the adhesive strength of the pressure-sensitive adhesive layer tends to decrease.
- the content of butorphanol and / or a pharmaceutically acceptable salt thereof contained in the pressure-sensitive adhesive layer is converted to butorphanol tartaric acid addition salt and per unit area of the pressure-sensitive adhesive layer.
- in content it is preferably from 0.2 ⁇ 2.0mg / cm 2, more preferably from 0.2 ⁇ 1.5mg / cm 2, is 0.2 ⁇ 1.2mg / cm 2 Is more preferable.
- butorphanol and / or a pharmaceutically acceptable salt thereof is less than the lower limit, the maximum skin permeation rate of butorphanol tends to decrease, whereas if it exceeds the upper limit, butorphanol crystals Tends to precipitate or the adhesive strength of the pressure-sensitive adhesive layer tends to decrease.
- the pressure-sensitive adhesive layer according to the present invention may further contain other drugs other than butorphanol and pharmaceutically acceptable salts thereof as long as the effects of the present invention are not impaired.
- the other drugs include non-steroidal anti-inflammatory analgesics (diclofenac, indomethacin, ketoprofen, ferbinac, loxoprofen, ibuprofen, flurbiprofen, thiaprofen, acemetacin, sulindac, etodolac, tolmetine, piroxicam, meloxicam, ampiroxicam, Naproxen, azapropazone, methyl salicylate, glycol salicylate, valdecoxib, celecoxib, rofecoxib, ampenac, etc., antipyretic analgesics (acetaminophen, etc.), antihistamines (diphenhydramine, chlorpheniramine, mequitazine, homochlorcyclodine, etc.
- the pressure-sensitive adhesive layer according to the present invention contains a pressure-sensitive adhesive base.
- the adhesive base include a rubber-based adhesive base, a silicone-based adhesive base, and an acrylic adhesive base, and among them, at least one selected from the group consisting of a rubber-based adhesive base and a silicone-based adhesive base. It is preferably a seed, and is a rubber-based adhesive base or a combination of a rubber-based adhesive base and a silicone-based adhesive base from the viewpoint of being able to exert a crystal precipitation suppressing effect in particular.
- the skin permeability of butorphanol is superior and has a higher level of adhesion to the skin (in the present invention, the adhesiveness of the patch means that the surface of the patch that is in contact with the skin is closely attached to the skin. It is more preferable to use a combination of a rubber-based adhesive base and a silicone-based adhesive base.
- the rubber-based adhesive base examples include natural rubber and synthetic rubber, and a styrene-isoprene-styrene block copolymer (from the viewpoint of maintaining sufficient adhesive strength as an adhesive layer of a patch) SIS), isoprene rubber, polyisobutylene (PIB), styrene-butadiene-styrene block copolymer (SBS), styrene-butadiene rubber (SBR), polybutene, and other polar functional groups (hydroxyl groups, carboxyl groups, amino groups, etc.) More preferably, it is at least one selected from the group consisting of synthetic rubbers not possessed.
- SIS styrene-isoprene-styrene block copolymer
- PIB polyisobutylene
- SBS styrene-butadiene-styrene block copolymer
- SBR styrene-butadiene rubber
- these rubber-based adhesive bases may be used singly or in combination of two or more, but they tend to maintain more sufficient adhesive strength as the adhesive layer of the patch.
- SIS or PIB is used alone, or the mass ratio of SIS and PIB (mass of SIS: mass of PIB) is in the range of 9: 1 to 1: 9 (more preferably 9: 1 to It is particularly preferable to use it in combination so as to be in the range of 1: 3.
- the silicone-based adhesive base refers to a polymer (polysiloxane) containing a siloxane unit represented by the following structural formula (2) and having a siloxane bond (—Si—O—) as a main chain.
- n represents a number of 2 or more.
- R 1 and R 2 each independently represent a group bonded to each Si atom.
- R 1 and R 2 are not particularly limited, but are preferably each independently a hydrogen atom, a hydroxyl group, an alkyl group, an alkenyl group, an aryl group, or an alkoxy group.
- the polymer may be linear, branched, or cyclic, or a composite of these.
- the terminal of the polymer is not particularly limited, but is preferably independently a hydrogen atom, a hydroxyl group, an alkyl group, an alkenyl group, an aryl group, an alkoxy group, a trimethylsilyl group, or a trimethylsilyloxy group.
- silicone-based adhesive base in ASTM standard (ASTM D 1418), MQ (polydimethylsiloxane, R 1 and R 2 in formula (2) are methyl groups), VMQ (polymethylvinylsiloxane), PMQ ( Polymethylphenylsiloxane), silicone rubber represented by PVMQ (polyphenylvinylmethylsiloxane), and mixtures of at least one of these with silicone resins other than silicone rubber such as polyditrimethylsilylsiloxane, etc. One of them may be used alone, or two or more may be used in combination. When a silicone resin other than the silicone rubber is mixed, it is preferably 0.1 to 20% by mass relative to the total mass of the silicone-based adhesive base.
- the silicone-based adhesive base according to the present invention may contain at least one silicone rubber selected from the group consisting of polydimethylsiloxane, polymethylvinylsiloxane, polymethylphenylsiloxane, and polyphenylvinylmethylsiloxane. preferable.
- the silanol groups of the silicone rubber are each independently capped with an alkyl group, an alkenyl group, an aryl group, an alkoxy group, a trimethylsilyl group, or a trimethylsilyloxy group (end). More preferably, it has been capped.
- silicone-based adhesive bases commercially available ones may be used, for example, the following model numbers from Dow Corning: BIO-PSA7-410X, BIO-PSA7-420X, BIO-PSA7- 430X, BIO-PSA7-440X, BIO-PSA7-450X, BIO-PSA7-460X (each X is independently 1 or 2), BIO-PSA AC7-4201, BIO-PSA AC7-4301, BIO -Using a silicone adhesive provided by PSA AC7-4302, MD7-4502, MD7-4602, 7-9700, MG7-9800, MG7-9850, BIO-PSA 7-4560 (hot melt silicone adhesive), etc. Even if one of these is used alone, two or more It may be used in combination.
- the silicone-based adhesive base for the purpose of enhancing the cohesiveness of the adhesive layer, for example, when it has a methyl group, the hydrogen atom of the methyl group is dehydrogenated by adding a peroxide.
- a cross-linking agent comprising a SiH group-containing siloxane compound is bonded to cross-link the vinyl group; in the case of having a hydroxyl group (that is, a silanol group) In the case where the silanol groups are cross-linked by dehydration condensation.
- acrylic adhesive base examples include acrylic acid / acrylic acid octyl ester copolymers, 2-ethylhexyl vinyl acetate, and acrylic acid / acrylic acid copolymers which are listed as adhesives in the Pharmaceutical Additives Dictionary 2016 (edited by Japan Pharmaceutical Additives Association).
- the content of the pressure-sensitive adhesive base contained in the pressure-sensitive adhesive layer (the total content in the case of a combination of two or more) is based on the total mass of the pressure-sensitive adhesive layer.
- the content is preferably 15 to 96% by mass, and more preferably 20 to 90% by mass.
- the content of the adhesive base is less than the lower limit, the adhesive strength of the adhesive layer tends to be reduced.
- the content exceeds the upper limit the skin permeability of butorphanol tends to be reduced.
- the content thereof when the rubber-based adhesive base is contained as the adhesive base in the adhesive layer, the content thereof is 5 to 95% by mass with respect to the total mass of the adhesive layer. It is preferably 15 to 95% by mass, more preferably 20 to 95% by mass.
- the content of the rubber-based adhesive base is less than the lower limit, the adhesive strength of the adhesive layer tends to be reduced.
- the content exceeds the upper limit the skin permeability of butorphanol tends to be reduced.
- the content of the rubber-based adhesive base is 5 to 5 based on the total mass of the adhesive layer. It is preferably 95% by mass, more preferably 5 to 85% by mass, still more preferably 5 to 50% by mass, and particularly preferably 7 to 40% by mass.
- the content of the rubber-based adhesive base is less than the lower limit, the effect of improving the adhesiveness of the adhesive layer to the skin tends not to be sufficiently achieved. It tends to be difficult to uniformly mix with the adhesive base.
- the content of the silicone-based adhesive base is relatively reduced, so that the adhesiveness of the adhesive layer to the skin, in particular, the effect of improving the adhesiveness under hot / cold water conditions or high humidity conditions Tend not to be fully played.
- the silicone adhesive base when the silicone adhesive base is contained as the adhesive base in the adhesive layer, the content thereof is 1 to 95% by mass with respect to the total mass of the adhesive layer. It is preferably 5 to 95% by mass, more preferably 5 to 85% by mass.
- the content of the silicone-based adhesive base is less than the lower limit, the adhesive strength of the adhesive layer tends to be reduced.
- the content exceeds the upper limit the skin permeability of butorphanol tends to be reduced.
- the content of the silicone-based adhesive base is from 1 to the total mass of the adhesive layer. It is preferably 47% by mass, more preferably 1 to 45% by mass, still more preferably 1 to 42% by mass, still more preferably 1 to 38% by mass, and even more preferably 1 to 36% by mass. % Is particularly preferred.
- the content of the silicone-based pressure-sensitive adhesive base is less than the lower limit, the adhesiveness of the pressure-sensitive adhesive layer to the skin, in particular, the effect of improving the adhesion property under hot / cold water conditions or high humidity conditions tends not to be sufficiently achieved. It is in.
- the above upper limit is exceeded, the content of the rubber-based adhesive base is relatively reduced, so that the adhesive strength of the adhesive layer tends to decrease. It tends to be difficult to mix with the base uniformly.
- the said rubber adhesive base and the said silicone adhesive base are contained as the said adhesive base in the said adhesive layer, the said rubber adhesive base, the said silicone adhesive base,
- the mass ratio (mass of rubber-based adhesive base: mass of silicone-based adhesive base) is preferably 9.5: 0.5 to 1.9: 8.1, and 9.5: 0. It is more preferably 5 to 2.5: 7.5, still more preferably 9.5: 0.5 to 3.0: 7.0, and 9.5: 0.5 to 4.0: Particularly preferred is 6.0.
- the ratio is from 4 to 1.9: 8.1, and it is particularly preferable that the ratio is from 5.0: 5.0 to 2.5: 7.5.
- the content of the silicone-based adhesive base relative to the rubber-based adhesive base is less than the lower limit, the adhesiveness of the adhesive layer to the skin, in particular, the effect of improving the adhesiveness under hot / cold water conditions or high humidity conditions Tend not to be fully played.
- the adhesive layer is not sufficiently improved in adhesion to the skin, or the rubber-based adhesive base and the silicone-based adhesive base tend not to be uniformly mixed during production. It is in.
- the pressure-sensitive adhesive layer according to the present invention contains an antioxidant having a sulfur atom in the molecule as an antioxidant.
- an antioxidant having the sulfur atom in the molecule By further containing an antioxidant having the sulfur atom in the molecule, the production of butorphanol oxidant can be remarkably suppressed without degrading basic performance such as skin permeability of the drug.
- antioxidant having a sulfur atom in the molecule according to the present invention examples include imidazole antioxidants (such as 2-mercaptobenzimidazole (2-MBI)), sodium pyrosulfite, sodium thioglycolate, N-acetyl. Cysteine and thioglycerol are preferred examples, and one of these may be used alone or two or more may be used in combination.
- imidazole antioxidants such as 2-mercaptobenzimidazole (2-MBI)
- sodium pyrosulfite sodium thioglycolate, N-acetyl.
- Cysteine and thioglycerol are preferred examples, and one of these may be used alone or two or more may be used in combination.
- at least one selected from imidazole antioxidants from the viewpoint that the effect of suppressing the production of butorphanol oxidant tends to be particularly high. More preferably, it is a seed, and 2-mercaptobenzimidazole is particularly preferable.
- the content of the antioxidant having sulfur atoms contained in the pressure-sensitive adhesive layer in the molecule (in the case of a combination of two or more, the total content thereof, the same shall apply hereinafter)
- the content is preferably 0.01 to 2.0% by mass, more preferably 0.01 to 1.0% by mass, and 0.04 to 1.0% by mass with respect to the total mass of the pressure-sensitive adhesive layer. More preferably, it is still more preferably 0.05 to 1.0% by mass, particularly preferably 0.1 to 1.0% by mass, and 0.1 to 0.5% by mass. More preferably. If the content of the antioxidant having the sulfur atom in the molecule is less than the lower limit, the effect of suppressing the production of butorphanol oxidant tends to be reduced. There is a tendency that the effect of suppressing the formation of oxidized butorphanol is not expected.
- the pressure-sensitive adhesive layer according to the present invention may further contain an antioxidant other than the antioxidant having the sulfur atom in the molecule as long as the effect of the present invention is not impaired.
- the other antioxidants include phenolic antioxidants such as dibutylhydroxytoluene (BHT) and butylhydroxyanisole (BHA); tocopherols and ester derivatives thereof; organic acids such as ascorbic acid and citric acid; ascorbic acid Examples include fatty acid esters such as palmitic acid ester and ascorbic acid stearic acid ester; paraben compounds such as methyl paraben and ethyl paraben; and organic acid salts such as sodium citrate, sodium EDTA, and EDTA. You may use it, or may use it in combination of 2 or more types.
- the total content is 5.0% by mass or less based on the total mass of the pressure-sensitive adhesive layer. preferable.
- the pressure-sensitive adhesive layer according to the present invention may further contain an absorption enhancer (transdermal absorption enhancer) as long as the effects of the present invention are not impaired.
- absorption enhancer include at least one selected from the group consisting of aliphatic alcohols, fatty acid esters, fatty acid amides, and aliphatic alcohol ethers.
- Jmax maximum skin permeation rate of butorphanol Is at least one selected from the group consisting of an aliphatic alcohol and a fatty acid ester, from the viewpoint that tends to be particularly large.
- the aliphatic alcohol according to the present invention is preferably a monovalent aliphatic alcohol having 6 to 20 carbon atoms.
- the aliphatic alcohol having 6 to 20 carbon atoms include lauryl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol, isostearyl alcohol, oleyl alcohol, linolenyl alcohol, octyldodecanol, and mixtures thereof. .
- At least one selected from the group consisting of isostearyl alcohol, oleyl alcohol, and octyldodecanol is particularly preferable from the viewpoint that the skin permeability of butorphanol tends to be better.
- fatty acid esters examples include alkyl esters of fatty acids having 6 to 20 carbon atoms (fatty acid alkyl esters), esters of fatty acids having 6 to 20 carbon atoms and glycerin or polyglycerin (glycerin fatty acid esters), At least 1 selected from the group consisting of esters of fatty acids having 6 to 20 with polyoxyalkylene (polyoxyalkylene fatty acid esters) and esters of fatty acids with 6 to 20 carbon atoms with saccharides (fatty acid esters of saccharides). Preferably it is a seed.
- the fatty acid alkyl ester is an ester compound of a fatty acid having 6 to 20 carbon atoms and a lower alkyl alcohol.
- fatty acid alkyl esters include isopropyl myristate, oleyl oleate, isopropyl palmitate, triethyl citrate, ethyl linoleate, hexyl laurate, cetyl myristate, octyldodecyl myristate, decyl oleate, oleic acid Octyldodecyl, octyldodecyl neodecanoate, cetyl ethylhexanoate, cetyl palmitate, stearyl stearate, and mixtures thereof.
- at least one selected from the group consisting of isopropyl myristate and isopropyl palmitate is preferable from the viewpoint that the skin
- examples of the glycerol fatty acid ester include glycerol monolaurate (monolaurin), polyglycerol monolaurate, glycerol monostearate (monostearin), polyglycerol monostearate, and glycerol monooleate (monoolein).
- the degree of polymerization of the polyglycerin is preferably 50 or less.
- the glycerol fatty acid ester is selected from the group consisting of glycerol monolaurate, polyglycerol monolaurate, glycerol monostearate, polyglycerol monostearate, glycerol monooleate, and polyglycerol monooleate. At least one of these is preferred.
- the glycerin fatty acid ester may be one in which a polyoxyethylene (POE) group is further added to the OH group of glycerin.
- POE polyoxyethylene
- the degree of polymerization of oxyethylene in the polyoxyethylene group is preferably 50 or less.
- the polyoxyalkylene fatty acid ester includes ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, a copolymer compound of oxyethylene and oxypropylene, and the like on the carboxy group portion of the fatty acid having 6 to 20 carbon atoms. It is a compound in which polyoxyalkylene is ester-bonded.
- Examples of such polyoxyalkylene fatty acid esters include ethylene glycol monolaurate, polyoxyethylene monolaurate (hereinafter, polyoxyethylene is sometimes referred to as “POE” and oxyethylene is referred to as “OE”), propylene glycol.
- Monolaurate PGML
- polyoxypropylene is sometimes referred to as “POP” and oxypropylene as “OP”
- ethylene glycol monopalmitate POE monopalmitate
- Propylene glycol monopalmitate POP monopalmitate
- ethylene glycol monostearate POE monostearate
- propylene glycol monostearate POP monostearate
- ethylene glycol monooleate POE monooleate propylene glycol monooleate
- POP monooleate dioleate propylene glycol, polyethylene glycol distearate.
- the degree of polymerization is preferably independently 50 or less.
- the polyoxyalkylene fatty acid ester is particularly preferably propylene glycol monolaurate from the viewpoint that the maximum skin permeation rate (Jmax) of butorphanol tends to be particularly large.
- the fatty acid ester of a saccharide is a compound in which a saccharide is ester-bonded to a carboxy group portion of a fatty acid having 6 to 20 carbon atoms.
- the saccharide include 4 monosaccharides (erythrose, threose), 5 monosaccharides (xylose, arabinose), 6 monosaccharides (glucose, galactose), sugar alcohols (xylitol, sorbitol), 2 sugars (sucrose, lactose, maltose) ) And the like.
- Such saccharide fatty acid esters include sorbitan monolaurate (span 20), sorbitan monopalmitate (span 40), sorbitan monostearate (span 60), sorbitan tristearate (span 65), sorbitan monooleate (Span 80), sorbitan trioleate, sorbitan sesquioleate (span 83).
- the fatty acid ester of the saccharide may be one in which a polyoxyethylene (POE) group is further added to the OH group in the sugar residue.
- POE polyoxyethylene
- the degree of polymerization of oxyethylene in the polyoxyethylene group is preferably 50 or less.
- examples of such compounds include polysorbate 20 (Tween 20), polysorbate 40 (Tween 40), polysorbate 60 (Tween 60), polysorbate 65 (Tween 65), polysorbate 80 (Tween 80), and the like.
- fatty acid amides examples include amides of fatty acids having 6 to 20 carbon atoms, such as lauric acid diethanolamide, oleic acid diethanolamide, stearic acid diethanolamide, ethylenebis-stearic acid amide, stearic acid monoamide. Oleic acid monoamide, ethylene bis-oleic acid amide, erucic acid monoamide, and mixtures thereof.
- the aliphatic alcohol ether includes an ethylene glycol, polyethylene glycol, propylene glycol, polypropylene glycol, a copolymer of oxyethylene and oxypropylene, a glycerin in the OH group portion of the aliphatic alcohol having 6 to 20 carbon atoms. And a compound in which polyoxyalkylene such as polyglycerin is ether-bonded.
- Examples of such aliphatic alcohol ethers include POE oleyl ether, POE lauryl ether, POE cetyl ether, POE stearyl ether, POE octyldodecyl ether, POE palmityl ether, and mixtures thereof.
- absorption promoter examples include POE hydrogenated castor oil, lecithins, phospholipids, soybean oil derivatives, triacetin and the like.
- the absorption accelerator is preferably a surface active compound that functions as a surface active agent.
- a surface active compound include propylene glycol monolaurate, sorbitan monooleate, glycerin monolaurate, glycerin monooleate, polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80 among the above. At least one selected from is preferred.
- the surface active compound is preferably nonionic.
- the content of the absorption accelerator with respect to the total mass of the pressure-sensitive adhesive layer is preferably 1 to 30% by mass, and more preferably 1 to 20% by mass.
- the content of the absorption accelerator is within the above range, the skin permeation rate of butorphanol tends to be increased.
- an adsorbent As a pressure-sensitive adhesive layer according to the present invention, an adsorbent, a desalting agent, a tackifier, a plasticizer, a solubilizer for drugs, a filler, a stabilizer, and storage are used as long as the effects of the present invention are not impaired.
- An additive such as an agent may be further contained.
- the adsorbent examples include hygroscopic inorganic and / or organic substances, and more specifically, minerals such as talc, kaolin, and bentonite; fumed silica (Aerosil (registered trademark), etc.), hydrous silica Silicon compounds such as zinc oxide, metal compounds such as dry aluminum hydroxide gel; weak acids such as lactic acid and acetic acid; sugars such as dextrin; Among them, one of these may be used alone, or two or more may be used in combination. Among these, it is preferable that the pressure-sensitive adhesive layer according to the present invention further contains polyvinylpyrrolidone (PVP) from the viewpoint of further suppressing the precipitation of butorphanol crystals.
- PVP polyvinylpyrrolidone
- the content thereof is 0.05 to 2 mg / cm 2 as a content per unit area of the pressure-sensitive adhesive layer. It is preferable that the content is 1 to 20% by mass based on the total mass of the pressure-sensitive adhesive layer. Further, the mass ratio of butorphanol and / or its pharmaceutically acceptable salt (mass weight of tartaric acid addition salt of butorphanol and / or its pharmaceutically acceptable salt: mass of polyvinylpyrrolidone) is 20: 1 to 1 : It is preferable that the amount is 10.
- the content of the polyvinyl pyrrolidone is less than the lower limit, the effect of suppressing further crystallization of butorphanol tends to be hardly achieved.
- the content exceeds the upper limit the skin permeability of butorphanol is decreased. Or the adhesive strength of the pressure-sensitive adhesive layer tends to decrease.
- the desalting agent is blended mainly for the purpose of converting all or part of the basic drug into a free form (free form).
- a desalting agent is not particularly limited.
- a desalting agent in the case of obtaining a preparation containing a butorphanol-free form by blending an acid addition salt of butorphanol as the drug, it is preferably a basic substance.
- metal ion-containing desalting agents and basic nitrogen atom-containing desalting agents.
- the metal ion-containing desalting agent include sodium acetate (including anhydrous sodium acetate), sodium hydroxide, potassium hydroxide, magnesium hydroxide, sodium hydrogen carbonate, potassium hydrogen carbonate, sodium citrate, sodium lactate and the like.
- the pressure-sensitive adhesive layer according to the present invention further contains a compound derived from the basic drug and the desalting agent (for example, sodium tartrate when butorphanol tartrate is combined with sodium acetate). Also good.
- a desalting agent and a compound derived from a basic drug and a desalting agent are further contained in the pressure-sensitive adhesive layer, the content thereof is butorphanol from the viewpoint of suppressing the decomposition of the drug.
- the acid-base equivalent of 1 in terms of tartaric acid addition salt is preferably 0.5 to 5 equivalents, more preferably 0.5 to 4 equivalents in terms of acid-base equivalents in terms of desalting agent.
- the tackifier is blended mainly for the purpose of increasing the adhesiveness of the adhesive base, preferably the rubber-based adhesive base.
- tackifiers include tackifier resins such as rosin resins, terpene resins, petroleum resins, phenolic resins, and xylene resins, and one of these can be used alone. May also be used in combination of two or more.
- the content in the case of a combination of two or more thereof, the total content thereof) is improved adhesive strength of the pressure-sensitive adhesive layer.
- 0.5 to 60% by mass more preferably 0.5 to 50% by mass with respect to the total mass of the pressure-sensitive adhesive layer.
- it is 3 to 50% by mass, more preferably 3 to 40% by mass.
- plasticizer The plasticizer is blended mainly for the purpose of adjusting the pressure-sensitive adhesive properties of the pressure-sensitive adhesive layer, the flow characteristics in the production of the pressure-sensitive adhesive layer, the transdermal absorption characteristics of the drug, and the like.
- plasticizers include silicone oils; petroleum oils such as paraffinic process oil, naphthenic process oil and aromatic process oil; squalane, squalene; olive oil, camellia oil, castor oil, tall oil and peanut oil.
- Vegetable oils such as: dibasic acid esters such as dibutyl phthalate and dioctyl phthalate; liquid rubbers such as polybutene and liquid isoprene rubber; diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, etc., one of these May be used alone or in combination of two or more.
- the plasticizer silicone oil, liquid paraffin, and liquid polybutene are preferable.
- the content in the case of a combination of two or more thereof, the total content thereof is improved adhesive strength of the pressure-sensitive adhesive layer and From the viewpoint of alleviating local irritation at the time of peeling, it is preferably 0.1 to 60% by mass, and preferably 0.5 to 25% by mass and 3 to 50% by mass with respect to the total mass of the adhesive layer. More preferred is 3 to 20% by mass.
- the solubilizer is blended mainly for the purpose of promoting dissolution of the drug.
- examples of such a solubilizer include organic acids such as acetic acid, aliphatic alcohols, and surfactants. One of these may be used alone, or two or more may be used in combination. Of these, organic acids and aliphatic alcohols are preferable as the solubilizer.
- filler The filler is blended mainly for the purpose of adjusting the adhesive strength of the pressure-sensitive adhesive layer.
- fillers include aluminum hydroxide, calcium carbonate, magnesium carbonate; silicates such as aluminum silicate and magnesium silicate; silicic acid, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, oxidation Titanium is mentioned, and one of these may be used alone or two or more may be used in combination.
- the total content is preferably 70% by mass or less based on the total mass of the pressure-sensitive adhesive layer.
- the total mass per unit area (the area of the sticking surface) is preferably 25 to 250 g / m 2 , and more preferably 40 to 200 g / m 2 .
- the mass per unit area is less than the lower limit, the skin permeability of butorphanol decreases, the adhesive strength of the adhesive layer decreases, or the thickness of the adhesive layer is difficult to control during production.
- the above upper limit is exceeded, the skin permeability of butorphanol is excessively increased as a patch intended for long-term sticking, or the thickness of the pressure-sensitive adhesive layer is difficult to control during production. Tend to.
- the area of the adhesive surface of the pressure-sensitive adhesive layer according to the present invention can be appropriately adjusted according to the purpose of treatment and the application target, and is usually in the range of 0.5 to 200 cm 2 .
- the patch of the present invention may be a package packaged (preferably enclosed) in a packaging container from the time of manufacture to the time of use.
- the packaging container is not particularly limited, and those that can be normally used as a packaging container for patches can be appropriately used.
- a plastic (for example, polyethylene) packaging bag, a metal layer (for example, an aluminum layer) is formed. It is preferable to use a plastic packaging bag, a metal packaging bag (for example, an aluminum packaging bag), or the like.
- the package in which the patch is packaged in the packaging container may further include a deoxygenation means.
- the oxygen scavenging means includes oxygen scavengers using iron powder and oxygen scavengers mainly composed of vitamin C (more specifically, the AGELESS series (Mitsubishi Gas Chemical Co., Ltd.). ), PharmaKeep series (Mitsubishi Gas Chemical Co., Ltd.), etc.); Deoxygenation layer (more specifically, powders of aluminum, zinc, manganese, copper, iron, hydrosulfite, activated carbon, etc. are mixed. And the like.
- the patch of the present invention is not particularly limited, and can be produced by appropriately adopting a known method for producing a patch.
- a known method for producing a patch For example, first, butorphanol and / or a pharmaceutically acceptable salt thereof, the adhesive base, an antioxidant having the sulfur atom in the molecule, and the absorption promoter, solvent or the additive as necessary are kneaded according to a conventional method to obtain a uniform pressure-sensitive adhesive layer composition.
- the solvent include absolute ethanol, toluene, heptane, methanol and the like.
- the pressure-sensitive adhesive layer composition is applied on the surface of the support layer (usually on one surface) so as to have a desired mass per unit area, and then the solvent is heated as necessary.
- the adhesive patch of the present invention can be obtained by drying to form a pressure-sensitive adhesive layer and further cutting it into a desired shape as necessary.
- the method for producing the patch of the present invention may further comprise a step of bonding the release liner on the surface of the pressure-sensitive adhesive layer opposite to the support layer, and the pressure-sensitive adhesive layer composition
- a pressure-sensitive adhesive layer is formed on one surface of the release liner so as to have a desired mass per unit area, and then the support is formed on the surface of the pressure-sensitive adhesive layer opposite to the release liner.
- the patch of the present invention may be obtained by laminating body layers and cutting into a predetermined shape as necessary. Furthermore, the obtained patch may be enclosed in the packaging container as necessary to form a package.
- the present invention will be described more specifically based on examples and comparative examples, but the present invention is not limited to the following examples.
- the oxidant amount measurement test, the crystal precipitation evaluation test, and the skin permeation test were performed by the methods shown below.
- ⁇ Oxidant amount measurement test> Immediately after production, after storage for 1 week at 60 ° C. in a polyethylene packaging bag and after storage for 3 months at 40 ° C. and 75% RH in a polyethylene packaging bag With respect to the patch (the area of the adhesive surface of the adhesive layer: 2.5 cm 2 ), the amount of oxidant in the adhesive layer was measured. For the measurement of the amount of oxidant, first, the release liner was removed from each patch and placed in a glass centrifuge tube, and 0.5 mL of tetrahydrofuran was added and shaken to dissolve the adhesive layer.
- Amount of oxidant [mass%] A T / A s ⁇ 100
- a T denotes the peak area area of butorphanol oxidant
- a s represents a peak area area of butorphanol and / or a salt thereof.
- the oxidant amount [% by mass] in the adhesive layer of each patch was calculated.
- the peak area of the butorphanol oxidant was defined as a peak area where the relative retention time (RRT) with respect to the retention time of butorphanol appears at a position near 0.24.
- ⁇ Skin penetration test in vitro hairless mouse skin penetration test
- the skin of the body of the hairless mouse was peeled to remove fat, and a patch was cut on the epidermis side to a size of 2.5 cm 2 and the release liner was removed. This was set in a flow-through type Franz-type permeation test cell so that the dermis side was in contact with the receptor solution, and the cell was filled with the receptor solution (PBS).
- the receptor solution is fed at a flow rate of about 2.5 ml / hr while circulating the heated circulating water around the outer periphery so that the receptor solution is kept at 32 ° C., and every 4 hours until 24 hours. Were collected.
- the concentration of butorphanol in the collected receptor solution was measured by high performance liquid chromatography, and the amount of butorphanol skin per hour per unit area of the adhesive layer (tartaric acid equivalent, unit: ⁇ g / unit) cm 2 / hr) was calculated, and this maximum value was taken as the maximum skin permeation rate (Jmax).
- silicone-based adhesive base silicone adhesive, model number: BIO-PSA7-4201, manufactured by Dow Corning
- SIS: PIB 4: 6 (mass ratio)
- tackifier resin tackifier resin
- plasticizer liquid paraffin
- the obtained pressure-sensitive adhesive layer composition is applied onto a release liner (a polyethylene terephthalate film subjected to a release treatment), and the solvent is removed by drying, so that the mass per unit area becomes 80 g / m 2.
- a release liner a polyethylene terephthalate film subjected to a release treatment
- a support layer polyethylene terephthalate film
- a support layer is laminated on the surface of the obtained pressure-sensitive adhesive layer opposite to the release liner to obtain a patch laminated in the order of support layer / pressure-sensitive adhesive layer / release liner. It was.
- Comparative Example 8 Adhering in the same manner as in Comparative Example 7 except that the rubber-based adhesive base, tackifier and plasticizer were not blended, and the composition of the pressure-sensitive adhesive layer composition was changed to the composition shown in Table 1 below. An agent was obtained.
- Example 2 Each patch was obtained in the same manner as in Example 1 except that the composition of the pressure-sensitive adhesive layer composition was changed to the composition shown in Table 2 below.
- Example 1 shows the composition of each adhesive layer composition of the patches obtained in Example 1 and Comparative Examples 1 to 9 (excluding the solvent), and immediately after production, after storage at 60 ° C. for 1 week, and 40 The amount of oxidant after storage at 3 ° C. (75% RH) for 3 months is shown.
- Table 2 shows the composition of each adhesive layer composition of the patches obtained in Examples 1 to 10 and Comparative Example 7 ( And the amount of oxidant immediately after production and after storage for 1 week at 60 ° C., respectively.
- Table 3 shows the results of a crystal precipitation evaluation test for the patches obtained in Examples 3, 4, 6, 7 and Comparative Example 7.
- Example 3, 4, 6, 7 and Comparative Example 7 there was no difference in the surface state of the pressure-sensitive adhesive layer among the three patches subjected to the crystal precipitation evaluation test, and the evaluation shown in Table 3 respectively. It was a result.
- Comparative Examples 10 to 13 The patch obtained in Comparative Example 7 was cut to a size of 2.5 cm 2 and each oxygen scavenger (Comparative Example 10: Ageless ZJ-15PT (Mitsubishi Gas Chemical Co., Ltd.)), Comparative Example 11: Pharmakeep KC (Mitsubishi Gas Chemical Co., Ltd.), Comparative Example 12: Pharmakeep KD (Mitsubishi Gas Chemical Co., Ltd.)) or without an oxygen scavenger (Comparative Example 13), each sealed in a polyethylene packaging bag. Each package was obtained.
- Example 11 to 12 Comparative Examples 14 to 15
- Example 12 Each patch was obtained in the same manner as in Example 1 except that the composition of the pressure-sensitive adhesive layer composition was changed to the composition shown in Table 5 below.
- the patches obtained in Examples 11 to 12 and Comparative Examples 14 to 15 were subjected to the above oxidant amount measurement test and crystal precipitation evaluation test, respectively.
- Table 5 shows the composition (excluding the solvent) of each adhesive layer composition of the patches obtained in Examples 11 to 12 and Comparative Examples 14 to 15, and immediately after production and after storage at 60 ° C. for 1 week. The amount of oxidant of each is shown.
- Table 6 shows the results of a crystal precipitation evaluation test on the patches obtained in Examples 11 to 12 and Comparative Examples 14 to 15, respectively. In each of Examples 11 to 12 and Comparative Examples 14 to 15, there was no difference in the surface state of the pressure-sensitive adhesive layer among the three patches subjected to the crystal precipitation evaluation test, and the evaluation results shown in Table 6 respectively. there were.
- the patch of the present invention in which 2-mercaptobenzimidazole (2-MBI), which is an antioxidant having a sulfur atom in the molecule, is blended as an antioxidant is butorphanol.
- 2-mercaptobenzimidazole (2-MBI) which is an antioxidant having a sulfur atom in the molecule
- the present invention it is possible to provide a patch in which the production of butorphanol oxidant is remarkably suppressed as compared with a conventional patch. Further, according to the present invention, since the crystal precipitation in the pressure-sensitive adhesive layer is further sufficiently suppressed, it is possible to provide a patch particularly excellent in stability over time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
本発明に係る粘着剤層は、薬物としてブトルファノール及びその薬学的に許容される塩からなる群から選択される少なくとも一種を含有する。本発明において、ブトルファノール(Butorphanol)とは、分子式C21H29NO2で表わされる17-(シクロブチルメチル)モルフィナン-3,14-ジオール(17-(Cyclobutylmethyl)morphinan-3,14-diol)を指す。
本発明に係る粘着剤層は、粘着基剤を含有する。前記粘着基剤としては、ゴム系粘着基剤、シリコーン系粘着基剤及びアクリル系粘着基剤が挙げられ、中でも、ゴム系粘着基剤及びシリコーン系粘着基剤からなる群から選択される少なくとも1種であることが好ましく、結晶析出抑制効果を特に発揮できる傾向にある観点からは、ゴム系粘着基剤であるか、又は、ゴム系粘着基剤とシリコーン系粘着基剤との組み合わせであることがより好ましく、ブトルファノールの皮膚透過性により優れ、かつ、より高水準の肌への付着性(本発明において、貼付剤の付着性とは、貼付剤の肌に接する面が肌にぴったりとついて剥がれない性質のことをいう)を発揮できるという観点からは、ゴム系粘着基剤とシリコーン系粘着基剤との組み合わせであることが更に好ましい。
本発明に係る粘着剤層は、抗酸化剤として、硫黄原子を分子内に有する抗酸化剤を含有する。前記硫黄原子を分子内に有する抗酸化剤を更に含有することにより、薬物の皮膚透過性等の基本的な性能を低下させることなく、ブトルファノール酸化体の生成を顕著に抑制することができる。
本発明に係る粘着剤層としては、本発明の効果を阻害しない範囲内において、吸収促進剤(経皮吸収促進剤)を更に含有していてもよい。前記吸収促進剤としては、例えば、脂肪族アルコール、脂肪酸エステル、脂肪酸アミド及び脂肪族アルコールエーテルからなる群から選択される少なくとも1種が挙げられ、これらの中でも、ブトルファノールの最大皮膚透過速度(Jmax)が特に大きくなる傾向にある観点から、脂肪族アルコール及び脂肪酸エステルからなる群から選択される少なくとも1種であることが好ましい。
本発明に係る脂肪族アルコールとしては、炭素数が6~20の一価の脂肪族アルコールであることが好ましい。脂肪族アルコールの炭素数が前記下限未満である場合には皮膚刺激性が強くなる傾向にあり、他方、前記上限を超える場合には、製剤中にロウ状の塊状物を生じる恐れがある。炭素数が6~20の脂肪族アルコールとしては、例えば、ラウリルアルコール、ミリスチルアルコール、セチルアルコール、ステアリルアルコール、イソステアリルアルコール、オレイルアルコール、リノレニルアルコール、オクチルドデカノール、及びこれらの混合物が挙げられる。これらの中でも、ブトルファノールの皮膚透過性がより良好となる傾向にあるという観点から、イソステアリルアルコール、オレイルアルコール、及びオクチルドデカノールからなる群から選択される少なくとも1種が特に好ましい。
本発明に係る脂肪酸エステルとしては、炭素数が6~20の脂肪酸のアルキルエステル(脂肪酸アルキルエステル)、炭素数が6~20の脂肪酸とグリセリン又はポリグリセリンとのエステル(グリセリン脂肪酸エステル)、炭素数が6~20の脂肪酸とポリオキシアルキレンとのエステル(ポリオキシアルキレン脂肪酸エステル)、及び炭素数が6~20の脂肪酸と糖類とのエステル(糖類の脂肪酸エステル)からなる群から選択される少なくとも1種であることが好ましい。
本発明に係る脂肪酸アミドとしては、炭素数が6~20の脂肪酸のアミドが挙げられ、例えば、ラウリン酸ジエタノールアミド、オレイン酸ジエタノールアミド、ステアリン酸ジエタノールアミド、エチレンビス-ステアリン酸アミド、ステアリン酸モノアミド、オレイン酸モノアミド、エチレンビス-オレイン酸アミド、エルカ酸モノアミド、及びこれらの混合物が挙げられる。
本発明において、前記脂肪族アルコールエーテルは、炭素数が6~20の脂肪族アルコールのOH基部分に、エチレングリコール、ポリエチレングリコール、プロピレングリコール、ポリプロピレングリコール、オキシエチレンとオキシプロピレンの共重合化合物、グリセリン、ポリグリセリン等のポリオキシアルキレンがエーテル結合した化合物である。このような脂肪族アルコールエーテルとしては、例えば、POEオレイルエーテル、POEラウリルエーテル、POEセチルエーテル、POEステアリルエーテル、POEオクチルドデシルエーテル、POEパルミチルエーテル、及びこれらの混合物が挙げられる。
本発明に係る粘着剤層としては、本発明の効果を阻害しない範囲内において、吸着剤、脱塩剤、粘着付与剤、可塑剤、薬物のための溶解剤、充填剤、安定化剤、保存剤等の添加剤を更に含有していてもよい。
前記吸着剤としては、吸湿性を有する無機及び/又は有機の物質が挙げられ、より具体的には、タルク、カオリン、ベントナイト等の鉱物;フュームドシリカ(アエロジル(登録商標)等)、含水シリカ等のケイ素化合物;酸化亜鉛、乾燥水酸化アルミニウムゲル等の金属化合物;乳酸、酢酸等の弱酸;デキストリン等の糖;ポリビニルピロリドン、アミノアルキルメタクリレートコポリマー、クロスポビドン、カルボキシビニルポリマー及びブチルメタクリレートメチルメタクリレートコポリマー等の高分子ポリマーが挙げられ、これらのうちの1種を単独で用いても2種以上を組み合わせて用いてもよい。これらの中でも、本発明に係る粘着剤層としては、ブトルファノールの結晶の析出をより抑制することが可能となる観点から、ポリビニルピロリドン(PVP)を更に含有することが好ましい。
前記脱塩剤は、主に塩基性薬物の全部又は一部をフリー体(遊離体)に変換することを目的として配合される。このような脱塩剤としては、特に限定はされないが、例えば、前記薬物としてブトルファノールの酸付加塩を配合してブトルファノールフリー体を含有する製剤を得る場合には、塩基性物質であることが好ましく、金属イオン含有脱塩剤、塩基性窒素原子含有脱塩剤であることがより好ましい。前記金属イオン含有脱塩剤としては、酢酸ナトリウム(無水酢酸ナトリウムを含む)、水酸化ナトリウム、水酸化カリウム、水酸化マグネシウム、炭酸水素ナトリウム、炭酸水素カリウム、クエン酸ナトリウム、乳酸ナトリウム等が挙げられ、これらのうちの1種を単独で用いても2種以上を組み合わせて用いてもよい。これらの中でも、前記脱塩剤としては、酢酸ナトリウム、水酸化ナトリウムが特に好ましい。なお、本発明に係る粘着剤層としては、前記塩基性薬物及び前記脱塩剤に由来する化合物(例えば、酒石酸ブトルファノールと酢酸ナトリウムとを組み合わせた場合には、酒石酸ナトリウム)を更に含有していてもよい。このような脱塩剤、並びに、塩基性薬物及び脱塩剤に由来する化合物が前記粘着剤層中に更に含有される場合、その含有量としては、薬物の分解を抑制するという観点から、ブトルファノールの酒石酸付加塩換算の酸塩基当量1に対して、脱塩剤換算の酸塩基当量で0.5~5当量であることが好ましく、0.5~4当量であることがより好ましい。
前記粘着付与剤は、主に前記粘着基剤、好ましくは前記ゴム系粘着基剤の粘着性を高めることを目的として配合される。このような粘着付与剤としては、例えば、ロジン系樹脂、テルペン系樹脂、石油系樹脂、フェノール系樹脂及びキシレン系樹脂等の粘着付与樹脂が挙げられ、これらのうちの1種を単独で用いても2種以上を組み合わせて用いてもよい。このような粘着付与剤が前記粘着剤層中に更に含有される場合、その含有量(2種以上の組み合わせである場合にはそれらの合計含有量)としては、粘着剤層の粘着力の向上及び/又は剥離時の局所刺激性の緩和という観点から、前記粘着剤層の全質量に対して0.5~60質量%であることが好ましく、0.5~50質量%であることがより好ましく、3~50質量%であることが更に好ましく、3~40質量%であることが特に好ましい。
前記可塑剤は、主に前記粘着剤層の粘着物性、前記粘着剤層の製造における流動特性、前記薬物の経皮吸収特性等を調整することを目的として配合される。このような可塑剤としては、例えば、シリコーンオイル;パラフィン系プロセスオイル、ナフテン系プロセスオイル及び芳香族系プロセスオイル等の石油系オイル;スクワラン、スクワレン;オリーブ油、ツバキ油、ひまし油、トール油及びラッカセイ油等の植物系オイル;ジブチルフタレート及びジオクチルフタレート等の二塩基酸エステル;ポリブテン及び液状イソプレンゴム等の液状ゴム;ジエチレングリコール、ポリエチレングリコール、プロピレングリコール、ジプロピレングリコール等が挙げられ、これらのうちの1種を単独で用いても2種以上を組み合わせて用いてもよい。これらの中でも、前記可塑剤としては、シリコーンオイル、流動パラフィン、液状ポリブテンが好ましい。このような可塑剤が前記粘着剤層中に更に含有される場合、その含有量(2種以上の組み合わせである場合にはそれらの合計含有量)としては、粘着剤層の粘着力の向上及び/又は剥離時の局所刺激性の緩和という観点から、前記粘着剤層の全質量に対して0.1~60質量%であることが好ましく、0.5~25質量%、3~50質量%であることがより好ましく、3~20質量%であることが更に好ましい。
前記溶解剤は、主に前記薬物の溶解を促進することを目的として配合される。このような溶解剤としては、例えば、酢酸等の有機酸、脂肪族アルコール、界面活性剤が挙げられ、これらのうちの1種を単独で用いても2種以上を組み合わせて用いてもよい。これらの中でも、前記溶解剤としては、有機酸、脂肪族アルコールが好ましい。
前記充填剤は、主に前記粘着剤層の粘着力を調整することを目的として配合される。このような充填剤としては、例えば、水酸化アルミニウム、炭酸カルシウム、炭酸マグネシウム;ケイ酸アルミニウムやケイ酸マグネシウム等のケイ酸塩;ケイ酸、硫酸バリウム、硫酸カルシウム、亜鉛酸カルシウム、酸化亜鉛、酸化チタンが挙げられ、これらのうちの1種を単独で用いても2種以上を組み合わせて用いてもよい。
製造直後、ポリエチレン製の包装袋に封入した状態で60℃において1週間保存後、及びポリエチレン製の包装袋に封入した状態で40℃、75%RHにおいて3ヶ月間保存後、の少なくともいずれかの貼付剤(粘着剤層の貼付面の面積:2.5cm2)について、それぞれ、粘着剤層中の酸化体量を測定した。酸化体量の測定は、先ず、各貼付剤から離型ライナーを除去してガラス製の遠沈管に入れ、テトラヒドロフラン0.5mLを加えて振とうし、粘着剤層を溶解させた。これに、アセトニトリルと水との混合液(アセトニトリル:水=1:1(体積比))5mLを更に加えて振とうした後、溶液の一部を採取してメンブレンフィルターで濾過した。次いで、得られた濾過液を試料溶液として、高速液体クロマトグラフ法により、試料溶液中のブトルファノール及び/又はその塩、並びに、ブトルファノール酸化体のピークエリア面積を求めた。高速液体クロマトグラフは、検出器:紫外吸光光度計(測定波長:280nm)、カラム:ODSカラムを用いて、試料注入後の時間:0~38.5分において、移動相A(12.6mM炭酸水素アンモニウム緩衝液(pH9.0))及び移動相B(メタノール)の混合比(移動相A/移動相B(体積比))が、55/45~35/65となるように濃度勾配を制御しておこなった。次いで、下記式:
酸化体量[質量%]=AT/As×100
[式中、ATはブトルファノール酸化体のピークエリア面積を示し、Asはブトルファノール及び/又はその塩のピークエリア面積を示す。]
により、各貼付剤の粘着剤層中の酸化体量[質量%]を算出した。なお、ブトルファノール酸化体のピークエリアは、ブトルファノールの保持時間に対する相対保持時間(RRT)が0.24付近の位置に現れるピークエリアをブトルファノール酸化体のピークエリアとした。
製造直後、未包装の状態で40℃、75%RHにおいて1日間保存後、未包装の状態で40℃、75%RHにおいて10日間保存後、及び未包装の状態で40℃、75%RHにおいて1ヶ月間保存後、の少なくともいずれかの貼付剤(粘着剤層の貼付面の面積:2.5cm2)について、それぞれ、粘着剤層における結晶析出の評価をした。評価は、貼付剤3枚について各粘着剤層の表面を目視で観察し、次の基準:
A:結晶析出が認められない
B:製剤として使用可能であるが、結晶析出が一部に認められる
C:結晶析出が全面に認められ、製剤として不適である
によって、各貼付剤の粘着剤層における結晶析出を評価した。
先ず、ヘアレスマウス胴体部の皮膚を剥離して脂肪を除去し、表皮側に2.5cm2の大きさに切断して離型ライナーを除去した貼付剤を貼付した。これを真皮側がレセプター液に接するようにフロースルータイプのフランツ型透過試験セルにセットし、前記セルにレセプター溶液(PBS)を満たした。次いで、レセプター溶液が32℃に保温されるように、暖めた循環水を外周部に循環させながら約2.5ml/hrの流速でレセプター溶液を送液し、4時間毎に24時間までレセプター溶液を採取した。採取したレセプター溶液中のブトルファノールの濃度(酒石酸換算)を高速液体クロマトグラフ法により測定し、各時間において、粘着剤層の単位面積における1時間あたりのブトルファノール皮膚透過量(酒石酸換算、単位:μg/cm2/hr)を算出し、この最大値を最大皮膚透過速度(Jmax)とした。
先ず、酒石酸ブトルファノール6.0質量部、シリコーン系粘着基剤(シリコーン粘着剤、型番:BIO-PSA7-4201、ダウ・コーニング社製)22.6質量部、ゴム系粘着基剤(SIS:PIB=4:6(質量比))19.1質量部、粘着付与剤(粘着付与樹脂)22.0質量部、可塑剤(流動パラフィン)11.7質量部、2-メルカプトベンズイミダゾール(2-MBI)0.5質量部、及びその他成分(脱塩剤、吸収促進剤及び吸着剤)18.1質量部を、適量の溶媒(無水エタノール及びトルエン)に加えて混合し、粘着剤層組成物を得た。次いで、得られた粘着剤層組成物を離型ライナー(離型処理が施されたポリエチレンテレフタレート製フィルム)上に塗布し、溶媒を乾燥除去して、単位面積あたり質量が80g/m2となるように粘着剤層を形成した。得られた粘着剤層の前記離型ライナーと反対の面上に支持体層(ポリエチレンテレフタレート製フィルム)を積層し、支持体層/粘着剤層/離型ライナーの順に積層された貼付剤を得た。
2-メルカプトベンズイミダゾール(2-MBI)に代えて各種抗酸化剤(比較例1:ジブチルヒドロキシトルエン、比較例2:ジブチルヒドロキシアニソール、比較例3:アスコルビン酸、比較例4:没食子酸プロピル、比較例5:トコフェロールアセテート、比較例6:EDTA・2ナトリウム)を配合し、粘着剤層組成物の配合組成を下記の表1に示す組成となるようにしたこと以外は実施例1と同様にして、各貼付剤を得た。
2-メルカプトベンズイミダゾール(2-MBI)を配合せず、粘着剤層組成物の配合組成を下記の表1に示す組成となるようにしたこと以外は実施例1と同様にして、貼付剤を得た。
ゴム系粘着基剤、粘着付与剤及び可塑剤を配合せず、粘着剤層組成物の配合組成を下記の表1に示す組成となるようにしたこと以外は比較例7と同様にして、貼付剤を得た。
シリコーン系粘着基剤、ゴム系粘着基剤、粘着付与剤及び可塑剤に代えてアクリル系粘着基剤(商品名:MAS811、コスメディ製薬株式会社製)を配合し、粘着剤層組成物の配合組成を下記の表1に示す組成となるようにしたこと以外は比較例7と同様にして、貼付剤を得た。
粘着剤層組成物の配合組成を下記の表2に示す組成となるようにしたこと以外は実施例1と同様にして、各貼付剤を得た。
比較例7で得られた貼付剤を2.5cm2の大きさに切断して各脱酸素剤(比較例10:エージレスZJ-15PT(三菱ガス化学株式会社製)、比較例11:ファーマキープKC(三菱ガス化学株式会社製)、比較例12:ファーマキープKD(三菱ガス化学株式会社製))と共に、又は脱酸素剤無し(比較例13)で、それぞれポリエチレン製の包装袋に入れて密封し、各包装体を得た。
粘着剤層組成物の配合組成を下記の表5に示す組成となるようにしたこと以外は実施例1と同様にして、各貼付剤を得た。
Claims (6)
- 支持体層及び粘着剤層を備える貼付剤であって、前記粘着剤層が、ブトルファノール及びその薬学的に許容される塩からなる群から選択される少なくとも1種と、粘着基剤と、硫黄原子を分子内に有する抗酸化剤と、を含有する貼付剤。
- 前記硫黄原子を分子内に有する抗酸化剤が、2-メルカプトベンズイミダゾールである請求項1に記載の貼付剤。
- 前記硫黄原子を分子内に有する抗酸化剤の含有量が、前記粘着剤層の全質量に対して0.01~2.0質量%である請求項1又は2に記載の貼付剤。
- 前記粘着基剤が、ゴム系粘着基剤及びシリコーン系粘着基剤からなる群から選択される少なくとも1種である請求項1~3のうちのいずれか一項に記載の貼付剤。
- 前記粘着剤層におけるブトルファノール及び/又はその薬学的に許容される塩の含有量が、ブトルファノール酒石酸付加塩換算で、前記粘着剤層の全質量に対して3~20質量%である請求項1~4のうちのいずれか一項に記載の貼付剤。
- 前記粘着剤層が、粘着付与剤及び可塑剤からなる群から選択される少なくとも1種を更に含有する請求項1~5のうちのいずれか一項に記載の貼付剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201880027050.5A CN110573160B (zh) | 2017-04-25 | 2018-04-19 | 贴附剂 |
US16/604,311 US10898448B2 (en) | 2017-04-25 | 2018-04-19 | Patch |
EP18791286.0A EP3616699B1 (en) | 2017-04-25 | 2018-04-19 | Adhesive patch |
JP2019514437A JP6773897B2 (ja) | 2017-04-25 | 2018-04-19 | 貼付剤 |
KR1020197026564A KR102302582B1 (ko) | 2017-04-25 | 2018-04-19 | 첩부제 |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-086357 | 2017-04-25 | ||
JP2017086357 | 2017-04-25 | ||
JP2017-129601 | 2017-06-30 | ||
JP2017129601 | 2017-06-30 | ||
JP2017129741 | 2017-06-30 | ||
JP2017-129741 | 2017-06-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018198925A1 true WO2018198925A1 (ja) | 2018-11-01 |
Family
ID=63919064
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/016117 WO2018198925A1 (ja) | 2017-04-25 | 2018-04-19 | 貼付剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10898448B2 (ja) |
EP (1) | EP3616699B1 (ja) |
JP (1) | JP6773897B2 (ja) |
KR (1) | KR102302582B1 (ja) |
CN (1) | CN110573160B (ja) |
TW (1) | TWI700103B (ja) |
WO (1) | WO2018198925A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7349591B1 (ja) * | 2021-11-04 | 2023-09-22 | 久光製薬株式会社 | カバー材付き貼付剤 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3775414A (en) | 1972-05-10 | 1973-11-27 | Bristol Myers Co | Process for the preparation of 14-hydroxymorphinan derivatives |
JPS6183116A (ja) * | 1984-08-10 | 1986-04-26 | イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− | オピオイドの経皮膚伝達 |
WO2005102393A1 (ja) * | 2004-04-21 | 2005-11-03 | Hisamitsu Pharmaceutical Co., Inc. | 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤 |
WO2009041714A1 (ja) * | 2007-09-26 | 2009-04-02 | Mikasa Seiyaku Co., Ltd. | フリーラジカル性疾患用外用剤 |
JP2012255043A (ja) * | 2006-12-01 | 2012-12-27 | Nitto Denko Corp | 安定化されたドネペジル含有貼付製剤 |
WO2016060122A1 (ja) | 2014-10-14 | 2016-04-21 | 久光製薬株式会社 | 貼付剤 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4626539A (en) | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US20060078600A1 (en) | 2003-02-07 | 2006-04-13 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof |
JP2006001859A (ja) | 2004-06-16 | 2006-01-05 | Shiseido Co Ltd | 絆創膏組成物 |
JP2006045099A (ja) | 2004-08-03 | 2006-02-16 | Teika Seiyaku Kk | 経皮吸収貼付剤 |
KR101408488B1 (ko) * | 2006-12-01 | 2014-06-17 | 닛토덴코 가부시키가이샤 | 도네페질 함유 접착 제제의 경시적인 변색을 억제하는 방법 |
JP2011515495A (ja) | 2008-03-26 | 2011-05-19 | オールトランツ インコーポレイティド | オピエートアゴニスト及びアゴニスト−アンタゴニストの乱用抑制経皮製剤 |
RU2543639C2 (ru) * | 2009-09-07 | 2015-03-10 | Нипро Пэтч Ко., Лтд. | Чрескожно всасывающийся препарат |
JP5725940B2 (ja) * | 2011-04-01 | 2015-05-27 | 日東電工株式会社 | ニコチン含有貼付製剤 |
JP5270035B1 (ja) | 2012-12-06 | 2013-08-21 | 久光製薬株式会社 | 貼付剤及びその製造方法 |
JP5415645B1 (ja) | 2013-06-28 | 2014-02-12 | 久光製薬株式会社 | 貼付剤の製造方法、貼付剤及び包装体 |
JPWO2016052522A1 (ja) * | 2014-09-30 | 2017-07-27 | ニプロ株式会社 | 経皮投与製剤及び包装体 |
-
2018
- 2018-04-19 JP JP2019514437A patent/JP6773897B2/ja active Active
- 2018-04-19 KR KR1020197026564A patent/KR102302582B1/ko active IP Right Grant
- 2018-04-19 EP EP18791286.0A patent/EP3616699B1/en active Active
- 2018-04-19 WO PCT/JP2018/016117 patent/WO2018198925A1/ja unknown
- 2018-04-19 CN CN201880027050.5A patent/CN110573160B/zh active Active
- 2018-04-19 US US16/604,311 patent/US10898448B2/en active Active
- 2018-04-25 TW TW107113989A patent/TWI700103B/zh active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3775414A (en) | 1972-05-10 | 1973-11-27 | Bristol Myers Co | Process for the preparation of 14-hydroxymorphinan derivatives |
JPS6183116A (ja) * | 1984-08-10 | 1986-04-26 | イ−・アイ・デユポン・ド・ネモア−ス・アンド・コンパニ− | オピオイドの経皮膚伝達 |
WO2005102393A1 (ja) * | 2004-04-21 | 2005-11-03 | Hisamitsu Pharmaceutical Co., Inc. | 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤 |
JP2012255043A (ja) * | 2006-12-01 | 2012-12-27 | Nitto Denko Corp | 安定化されたドネペジル含有貼付製剤 |
WO2009041714A1 (ja) * | 2007-09-26 | 2009-04-02 | Mikasa Seiyaku Co., Ltd. | フリーラジカル性疾患用外用剤 |
WO2016060122A1 (ja) | 2014-10-14 | 2016-04-21 | 久光製薬株式会社 | 貼付剤 |
Non-Patent Citations (3)
Title |
---|
M. SVOZIL ET AL., DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 33, no. 5, 2007, pages 559 - 567 |
See also references of EP3616699A4 |
SVOZIL, MICHAL ET AL.: "In vitro studies on transdermal permeation of butorphanol", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 33, no. 5, May 2007 (2007-05-01), pages 559 - 567, XP055527473, ISSN: 0363-9045 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7349591B1 (ja) * | 2021-11-04 | 2023-09-22 | 久光製薬株式会社 | カバー材付き貼付剤 |
Also Published As
Publication number | Publication date |
---|---|
TWI700103B (zh) | 2020-08-01 |
US10898448B2 (en) | 2021-01-26 |
KR102302582B1 (ko) | 2021-09-14 |
TW201841627A (zh) | 2018-12-01 |
US20200054575A1 (en) | 2020-02-20 |
JP6773897B2 (ja) | 2020-10-21 |
KR20190112811A (ko) | 2019-10-07 |
CN110573160B (zh) | 2022-11-18 |
EP3616699A4 (en) | 2020-06-17 |
EP3616699B1 (en) | 2021-06-09 |
EP3616699A1 (en) | 2020-03-04 |
CN110573160A (zh) | 2019-12-13 |
JPWO2018198925A1 (ja) | 2019-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6689443B2 (ja) | 貼付剤及びその包装体 | |
JP6773897B2 (ja) | 貼付剤 | |
JP6704514B2 (ja) | 貼付剤 | |
JP6865235B2 (ja) | ブトルファノール含有貼付剤 | |
JP6908800B1 (ja) | ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法 | |
JP7202450B2 (ja) | ロピニロール含有貼付剤の粘着剤層保持力向上方法、及びロピニロール含有保持力改善貼付剤 | |
JP7284877B2 (ja) | ロピニロール含有貼付剤及びロピニロールの皮膚透過性向上方法 | |
WO2024116965A1 (ja) | ロチゴチン含有貼付剤及びロチゴチン安定性向上方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18791286 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019514437 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20197026564 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018791286 Country of ref document: EP Effective date: 20191125 |